Pfizer locks employees out of India plant; GSK's Arzerra hit study endpoint;

@FiercePharma: Top news Thurs: What's the gleam in Sanofi CEO's eye? Could be Q2--or a canny PCSK9 maneuver. Article | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton

@EricPFierce: Amgen CEO says it is turning to new, manufacturing technology. That won't save nearly 500 production jobs. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Miss yesterday's issue of FierceVaccines? Subscribe here | Follow @CarlyHFierce

> Pfizer ($PFE) locked out some employees at a plant in India on Friday, saying that workers had disrupted production lines and threatened some managers. Story

> Pfizer is asking the Nevada Supreme Court to decide if the state's attorney general acted properly by hiring private law firms and agreeing to pay them a contingency fee to handle a case against the drugmaker. Story

> Idenix Pharmaceuticals ($IDIX), which is being bought by Merck ($MRK) for $3.8 billion, reported that it lost about $65 million in the second quarter but has about $178 million in cash on hand. Release

> GlaxoSmithKline ($GSK) said that the Independent Data Monitoring Committee's (IDMC) interim analysis of the PROLONG Phase III study found that its Arzerra hit the primary endpoint of improving progression-free survival in patients with relapsed chronic lymphocytic leukemia (CLL) who responded to treatment at relapse. Release

> European regulators have agreed to undertake an accelerated assessment of Eisai's lenvatinib as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer. Story

> Alexion Pharmaceuticals ($ALXN) announced that the European Commission has granted orphan drug designation (ODD) to Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG). Release

Medical Device News

@FierceMedDev: HeartWare celebrates record Q2 sales despite regulatory pushback. Story | Follow @FierceMedDev

@StacyALawrence: Device share of healthcare venture capital funding hits decade low. More | Follow @StacyALawrence

@VarunSaxena2: FDA announces intention to comprehensively regulate lab-developed tests. Article | Follow @VarunSaxena2

@MichaelGFierce: Nature-inspired artificial cilia could help move drugs to a target. Report | Follow @MichaelGFierce

@EmilyWFierce: Physicians weigh in on Johnson & Johnson's decision to withdraw power morcellator products from the market. More from the NYT | Follow @EmilyWFierce

> FDA announces intention to comprehensively regulate lab-developed tests. Story

> 3D Systems buys surgical virtual reality player for $120M, falls 11% on earnings miss. More

Biotech News

@FierceBiotech: FDA panel green-lights Baxter and Halozyme's drug on a second pass. News | Follow @FierceBiotech

@JohnCFierce: Top story for July: UPDATED: Amgen axing up to 2,900 staffers, shuttering R&D campus in revamp. Article | Follow @JohnCFierce

@DamianFierce: Last thing on priority review vouchers: Creators figured they'd have a market value of up to $500M. and paying just $67.5M. | Follow @DamianFierce

@EmilyMFierce: NIH to launch early Ebola vaccine trial in September. More from USAToday | Follow @EmilyMFierce

> Almirall seeks dermatology deals, Euro biotech IPOs fall short, Cellectis increases CAR-T focus. EuroBiotech report

> Venrock unveils a $450M new fund with eyes on biotech. News

> Sarepta looks to quiet controversy with a boardroom shakeup. Article

And Finally... Attorney General Eric Holder has said states should be open about the drugs used in lethal cocktails after a number of executions have been botched. Story

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.